Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Robert Schueren, William McKenzie

Premium

WaferGen has made changes to its board of directors following the firm's acquisition of IntegenX's next-gen sequencing library prep business. The company has reduced the size of its board of directors to seven from nine. In addition, Robert Schueren, IntegenX's CEO, will join WaferGen's board of directors. Prior to his role at IntegenX, Schueren was vice president and general manager of genomics at Agilent Technologies.

The board also appointed William McKenzie as a director, effective Dec. 30, 2013. Most recently, he served as president and general manager of molecular diagnostics at PerkinElmer.

Scott Davidson and Joseph Pesce, representatives of Great Point Partners, stepped down from the board, effective Dec. 30, 2013.

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.